Table 2. Novel resistance conferring mutations derived from the dataset (NNRTI).
Mutation | DLV | EFV | ETR | NVP | Average Log FC |
P9T | 0.36 | 1.01 | 0.65 | 0.46 | 0.62 |
E79D | 0.34 | 0.55 | 0.61 | 0.34 | 0.46 |
K101S | 0.38 | 0.73 | 0.31 | 0.44 | 0.47 |
K102Y | 0.72 | 0.53 | 0.47 | 0.77 | 0.62 |
S156A | 0.8 | 1.2 | 0.76 | 0.67 | 0.86 |
M164L | 0.26 | 0.89 | 0.51 | 0.62 | 0.57 |
T216M | 0.97 | 1.47 | 0.01 | 0.84 | 0.82 |
Y232H | 0.47 | 0.62 | 0.36 | 0.47 | 0.48 |
R307M | 0.92 | 0.14 | 0.28 | 0.35 | 0.42 |
Average Susceptibility | 0.58 | 0.79 | 0.44 | 0.55 | - |
The value in the different drug columns indicates the average Log FC in the presence of this mutation. While these mutations have been selected to confer some resistance to all NNRTIs, each drug still has a distinct profile. Efavirenz is the most sensitive (average Log FC 0.79) and Etravirine the least (average Log FC 0.44) with Nevirapine (average Log FC 0.55) and Delavirdine (average Log FC 0.58) in between.